Recently，Notice of the National Medical Security Bureau，Incorporate 18 anticancer drugs into the scope of special negotiation drugs for medical insurance access in 2018。There are 2 domestic enterprises，The rest are multinational companies，Novartis has 5 varieties selected。16 anti -cancer drugs，There are 6 sales of the terminal sales of Chinese public My stake betting appstake betting appmedical institutions in 2017 exceeding 100 million yuan，Among them, Novarton's injection of octoprotic acetate peptide micro -ball is close to 3 billion yuan。
Table 18 anticancer drugs incorporated into the special negotiation of medical insurance access
stake betting app
Figure 18 types of anticancer drug companies distribution
In 18 anticancer drugs incorporated into the special negotiations of medical insurance access，Domestic enterprises have 2 varieties selected，The Peimen enzyme injection (product name Aiyang) and Zhengda Tianqing Pharmaceutical Hydinib Capsule (product name Fumogovovi)，Ai Yang is the PEG-Asp injection solution independently developed by Hengrui，In 2009, it was approved by the State Drug Administration for listing in China，Fokevi is the new type 1.1 new medicine developed by Zhengda Tianqing，It was approved by the State Drug Administration in May this year。
16 varieties of multinational enterprises are selected，10 companies involved，Among them, the most varieties selected by Novartis，5，Antic acid reedinib tablets (product name Jie Kewei)、Nilotinib Capsules (product name Dahina)、Boriza Pani tablets (product name vitamin)My stake betting app、Serentinib Capsules (My stake betting appproduct name Zan Keada)、Actinicate Micro Speake (Product Names Good Dragon)，Among them, the sale of the terminal of the terminal of acetic acid acetate in the Chinese public medical institution was 2.885 billion yuan，increased by 5.41%year -on -year。Pfizer followed by 3 varieties.，Agechini tablets (product name Yinglida)、Kradinib Capsules (Sai Korui)、Apple acid Schunitinib Capsule (Mortan)。
Eribinic small molecules targeted anti -cancer drugs accounted for half of the country
In 18 anticancer drugs，The number of targeting drugs for small molecules of eastibiniomy is the most，There are 10 in total，Production enterprises are mainly multinational enterprises，Domestic enterprises have only Arotinib, which is only sunny。10 category drugs，Pfizer's Cizininib capsules and apple acid Schunitinib capsules、Novotini Capsules of Novarty in 2017 in China's public medical institution terminals exceeded 100 million yuan，Astroniconicine's oxitininib tablet was approved for listing in March 2017 with the State Drug Administration，In less than a year, it will account for 32.23 million yuan in drug market。
stake sports betting appIn recent years，The application stake sports betting appof monoclonal anti -anti -anti -tumor is also widely used in the field of anti -tumor。Merck's Siciel Ming Mingjiejiejin is the only monoclonal product in the special negotiation list of this medical insurance access，It was approved by the Pharmaceutical Supervision Bureau in November 2005，and officially listed in China in 2006。According to Mi Na.com data，2017 China Public Medical Institution Terminal Sitica Ming Mingjin Sales Sales of Sicie Settlement is 674 million yuan，At present, the domestic market has not yet been approved for listing。
Conclusion
A new round of anticancer drug medical insurance for special negotiations cover non -small cell lung cancer、colorectal cancer、renal cell carcinoma、melanoma、Chronic granulocyte leukemia、lymph cancer、Multiple cancer species such as multiple osteoma，All clinical drugs necessary for blood tumors and physical tumors。The relevant person in charge of the National Medical Insurance Bureau said，Since most of the medicines are in the patented drug protection period，But this special negotiation will reach a price reduction agreement with the company in the near future。
